CorMedix

186 articles about CorMedix

• Cormedix Inc. To Present At The Jefferies Healthcare Conference

  5/30/2023

  CorMedix Inc. today announced that management will be presenting and participating in investor meetings at the Jefferies Healthcare Conference being held in New York on June 7 – 9, 2023.

• CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

  5/15/2023

  CorMedix Inc. announced financial results for the first quarter ended March 31, 2023 and provided an update on recent business developments.

• CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023

  5/8/2023

  CorMedix Inc. today announced that it will report its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.

• CorMedix Inc. to Participate in Two Upcoming Investor Conferences

  5/3/2023

  CorMedix Inc. today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 15 – 16, 2023 and the 2023 RBC Capital Markets Global Healthcare Conference being held in New York on May 16 – 17, 2023.

• CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

  5/1/2023

  CorMedix Inc. (Nasdaq: CRMD) today announced that the United States Patent and Trademark Office (USPTO) allowed its patent claims directed to the composition of a catheter lock solution for preventing infection and also preventing reduced blood flow in central venous catheters.

• CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates

  4/26/2023

  CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, announced that following its Type A meeting with the FDA, the Company intends to resubmit its New Drug Application for DefenCath by the middle of May.

• Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

  4/17/2023

  CorMedix Inc. today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.

• CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/30/2023

  CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent business developments.

• Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023

  3/21/2023

  CorMedix Inc. today announced that it will report its financial results for the fourth quarter and year ended December 31, 2022, before the market opens on Thursday, March 30, 2023, and will host a corporate update conference call at 8:30am Eastern Time.

• CorMedix Inc. Announces Regulatory and Manufacturing Updates

  3/2/2023

  CorMedix Inc. announced updates related to the FDA compliance remediation activities at its primary contract manufacturing organization and heparin active pharmaceutical ingredient supplier, as well as updated timelines for potential resubmission of its New Drug Application under various scenarios.

• CorMedix Inc. Announces Promotions in Commercial and Tech Ops

  1/17/2023

  CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, announced the following promotions within the organization:

• Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections

  12/6/2022

  CorMedix Inc. today announced the abstract publication and poster presentation at the American Society of Health-System Pharmacists (ASHP) conference in Las Vegas, Nevada, December 4 – 8.

• CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business UpdateConference Call Scheduled for Today at 8:30 a.m. Eastern Time

  11/10/2022

  CorMedix Inc. today announced financial results for the third quarter and nine months ended September 30, 2022 and provided an update on recent business events.

• CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath

  11/7/2022

  CorMedix Inc. announced that the Center for Medicare & Medicaid Services has published in the Federal Register a correction to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals New Technology Add on Payment reimbursement of DefenCath, increasing the maximum reimbursement per average hospital visit from $4,387.50 to $14,259.38.

• CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10

  11/2/2022

  CorMedix Inc. today announced that it will report its financial results for the third quarter ended September 30, 2022, before the market open on Thursday, November 10, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

• CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

  10/20/2022

  CorMedix Inc. today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

• CorMedix Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  CorMedix Inc. announced that management will be presenting a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in New York on September 12 – 14, 2022.

• CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

  8/11/2022

  CorMedix Inc. today announced financial results for the second quarter and six months ended June 30, 2022 and provided an update on recent business events.

• CorMedix Inc. Announces Regulatory and Manufacturing Updates - Aug 08, 2022

  8/8/2022

  CorMedix Inc. announced updates related to the FDA review of the DefenCath New Drug Application as well as other manufacturing and commercial updates.

• CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11

  8/1/2022

  CorMedix Inc. today announced that it will report its financial results for the second quarter ended June 30, 2022, before the market open on Thursday, August 11, 2022, and will host a corporate update conference call at 8:30am Eastern Time.